Aldeyra Therapeutics, Inc.

DB:137 Stock Report

Market Cap: €286.7m

Aldeyra Therapeutics Management

Management criteria checks 2/4

Aldeyra Therapeutics' CEO is Todd Brady, appointed in Jan 2012, has a tenure of 12.92 years. total yearly compensation is $3.68M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 1.94% of the company’s shares, worth €5.56M. The average tenure of the management team and the board of directors is 3.9 years and 11.3 years respectively.

Key information

Todd Brady

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage15.8%
CEO tenure12.9yrs
CEO ownership1.9%
Management average tenure3.9yrs
Board average tenure11.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Todd Brady's remuneration changed compared to Aldeyra Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$4mUS$581k

-US$38m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$3mUS$559k

-US$62m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$3mUS$547k

-US$58m

Sep 30 2021n/an/a

-US$53m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$2mUS$544k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$55m

Dec 31 2019US$4mUS$523k

-US$61m

Sep 30 2019n/an/a

-US$58m

Jun 30 2019n/an/a

-US$50m

Mar 31 2019n/an/a

-US$46m

Dec 31 2018US$3mUS$506k

-US$39m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$2mUS$473k

-US$22m

Compensation vs Market: Todd's total compensation ($USD3.68M) is above average for companies of similar size in the German market ($USD900.29K).

Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.

CEO

Todd Brady (52 yo)

12.9yrs

Tenure

US$3,684,651

Compensation

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Brady
CEO, President & Director12.9yrsUS$3.68m1.94%
€ 5.6m
Stephen Machatha
Chief Development Officer3.9yrsUS$1.59m0.19%
€ 538.1k
Michael Alfieri
Principal Financial & Accounting Officerless than a yearno datano data
David Burke
Head of Investor Relationsno datano datano data
Laura Nichols
Operations Managerno datano datano data

3.9yrs

Average Tenure

52yo

Average Age

Experienced Management: 137's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Todd Brady
CEO, President & Director19.9yrsUS$3.68m1.94%
€ 5.6m
Richard Douglas
Independent Chair of the Board8.3yrsUS$221.98k0.21%
€ 601.8k
Ben Bronstein
Independent Director14.5yrsUS$190.40k0.047%
€ 136.0k
Gary Phillips
Independent Director15.6yrsUS$194.07k0.025%
€ 71.3k
Martin Joyce
Independent Director11.2yrsUS$195.66k0.040%
€ 115.4k
Neal Walker
Independent Director11.5yrsUS$174.22k0.027%
€ 76.3k
Jay Duker
Member of Retina Segment Scientific Advisory Boardno datano datano data
Paul Karpecki
Member of Anterior Segment Scientific Advisory Board4.9yrsno datano data
John Sheppard
Member of Anterior Segment Scientific Advisory Boardno datano datano data
Nancy Miller-Rich
Independent Director4.9yrsUS$174.22k0%
€ 0
Victor Perez
Member of Anterior Segment Scientific Advisory Boardno datano datano data
David Chu
Member of Anterior Segment Scientific Advisory Boardno datano datano data

11.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 137's board of directors are seasoned and experienced ( 11.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 05:00
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aldeyra Therapeutics, Inc. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Keay NakaeAscendiant Capital Markets LLC
Esther Lannie HongBerenberg